Effects of the CYP 2D6 Genotype and Cigarette Smoking on the Steady-State Plasma Concentrations of Fluvoxamine and Its Major Metabolite Fluvoxamino Acid in Japanese Depressed Patients
- 1 August 2003
- journal article
- research article
- Published by Wolters Kluwer Health in Therapeutic Drug Monitoring
- Vol. 25 (4) , 463-468
- https://doi.org/10.1097/00007691-200308000-00008
Abstract
The effects of the cytochrome P450 (CYP) 2D6 genotype and cigarette smoking on the steady-state plasma concentrations (Css) of fluvoxamine (FLV) and its demethylated metabolite fluvoxamino acid (FLA) were studied in 49 Japanese depressed patients receiving FLV 200 mg/d. The Css of FLV and FLA were measured by HPLC, and the wild-type allele (*1) and two mutated alleles causing absent (*5) or decreased (*10) CYP 2D6 activity were identified by PCR methods. The patients were divided into three genotype groups by the number of mutated alleles: 12 cases with no (*1/*1), 27 cases with one (*1/*5 and *1/*10), and 10 cases with two (*5/*10 and *10/*10) mutated alleles. The means ± SD of the Css of FLV and FLA and the FLA/FLV ratio of all patients were 169.1 ± 147.5 ng/mL, 83.9 ± 52.7 ng/mL, and 0.71 ± 0.50, respectively. The Css of FLV and FLA were not significantly different among the three genotype groups. However, the FLA/FLV ratio was significantly lower in the patients with one (P PKeywords
This publication has 38 references indexed in Scilit:
- Pharmacogenetics of Classical and New Antipsychotic DrugsTherapeutic Drug Monitoring, 2000
- Lack of correlation between fluvoxamine clearance and CYP1A2 activity as measured by systemic caffeine clearanceEuropean Journal of Clinical Pharmacology, 1999
- Relationship between fluvoxamine pharmacokinetics and CYP2D6/CYP2C19 phenotype polymorphismsEuropean Journal of Clinical Pharmacology, 1997
- Disposition of fluvoxamine in humans is determined by the polymorphic CYP2D6 and also by the CYP1A2 activity*Clinical Pharmacology & Therapeutics, 1996
- Polymorphic Drug OxidationCNS Drugs, 1996
- Effect of cigarette smoking on fluvoxamine pharmacokinetics in humansClinical Pharmacology & Therapeutics, 1995
- The influence of environmental and genetic factors on CYP2D6, CYP1A2 and UDP-glucuronosyltransferases in man using sparteine, caffeine, and paracetamol as probesPharmacogenetics, 1994
- FluvoxamineDrugs, 1993
- Fluvoxamine maleate: metabolism in manEuropean Journal of Drug Metabolism and Pharmacokinetics, 1983
- Review of the animal pharmacology and pharmacokinetics of fluvoxamine.British Journal of Clinical Pharmacology, 1983